+

SE9003665D0 - Morphine prodrugs - Google Patents

Morphine prodrugs

Info

Publication number
SE9003665D0
SE9003665D0 SE9003665A SE9003665A SE9003665D0 SE 9003665 D0 SE9003665 D0 SE 9003665D0 SE 9003665 A SE9003665 A SE 9003665A SE 9003665 A SE9003665 A SE 9003665A SE 9003665 D0 SE9003665 D0 SE 9003665D0
Authority
SE
Sweden
Prior art keywords
pct
morphine
date
sec
prodrugs
Prior art date
Application number
SE9003665A
Other languages
English (en)
Swedish (sv)
Inventor
H Bundgaard
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to SE9003665A priority Critical patent/SE9003665D0/xx
Publication of SE9003665D0 publication Critical patent/SE9003665D0/xx
Priority to IE368291A priority patent/IE913682A1/en
Priority to NZ240349A priority patent/NZ240349A/en
Priority to ZA918512A priority patent/ZA918512B/xx
Priority to IL9990591A priority patent/IL99905A/en
Priority to DE69129861T priority patent/DE69129861T2/de
Priority to AT91920399T priority patent/ATE168560T1/de
Priority to EP91920399A priority patent/EP0557385B1/fr
Priority to CA002095223A priority patent/CA2095223C/fr
Priority to DK91920399T priority patent/DK0557385T3/da
Priority to ES91920399T priority patent/ES2121793T3/es
Priority to AU89381/91A priority patent/AU655612B2/en
Priority to US08/050,336 priority patent/US5908846A/en
Priority to PCT/SE1991/000760 priority patent/WO1992008459A1/fr
Priority to JP50056892A priority patent/JP3493434B2/ja
Priority to PT99513A priority patent/PT99513B/pt
Priority to NO931766A priority patent/NO931766D0/no
Priority to FI932212A priority patent/FI932212A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9003665A 1990-11-16 1990-11-16 Morphine prodrugs SE9003665D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE9003665A SE9003665D0 (sv) 1990-11-16 1990-11-16 Morphine prodrugs
IE368291A IE913682A1 (en) 1990-11-16 1991-10-21 Morphine prodrugs
NZ240349A NZ240349A (en) 1990-11-16 1991-10-25 Topical compositions for transdermal delivery of morphine prodrugs
ZA918512A ZA918512B (en) 1990-11-16 1991-10-25 Morphine prodrugs
IL9990591A IL99905A (en) 1990-11-16 1991-10-30 Topical compositions for transdermal delivery of morphine prodrugs
JP50056892A JP3493434B2 (ja) 1990-11-16 1991-11-11 モルヒネのプロドラッグ誘導体の経皮供給用の局所組成物
CA002095223A CA2095223C (fr) 1990-11-16 1991-11-11 Compositions topiques pour l'administration transdermique de derives de precurseurs de morphine
AT91920399T ATE168560T1 (de) 1990-11-16 1991-11-11 Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
EP91920399A EP0557385B1 (fr) 1990-11-16 1991-11-11 Compositions a administration locale destinees a l'asministration transdermique de derives de promedicament de morphine
DE69129861T DE69129861T2 (de) 1990-11-16 1991-11-11 Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
DK91920399T DK0557385T3 (da) 1990-11-16 1991-11-11 Topiske sammensætninger til transdermal afgivelse af prodrug-derivater af morfin
ES91920399T ES2121793T3 (es) 1990-11-16 1991-11-11 Composiciones de uso local para la administracion transdermica de derivados profarmacos de morfina.
AU89381/91A AU655612B2 (en) 1990-11-16 1991-11-11 Topical compositions for transdermal delivery of produg derivatives of morphine
US08/050,336 US5908846A (en) 1990-11-16 1991-11-11 Topical compositions for transdermal delivery of prodrug derivatives of morphine
PCT/SE1991/000760 WO1992008459A1 (fr) 1990-11-16 1991-11-11 Compositions a administration locale destinees a l'asministration transdermique de derives de promedicament de morphine
PT99513A PT99513B (pt) 1990-11-16 1991-11-14 Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
NO931766A NO931766D0 (no) 1990-11-16 1993-05-14 Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
FI932212A FI932212A0 (fi) 1990-11-16 1993-05-14 Topikal kompositioner foer transdermal transmission av morfinets prodrugderivat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9003665A SE9003665D0 (sv) 1990-11-16 1990-11-16 Morphine prodrugs

Publications (1)

Publication Number Publication Date
SE9003665D0 true SE9003665D0 (sv) 1990-11-16

Family

ID=20380936

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9003665A SE9003665D0 (sv) 1990-11-16 1990-11-16 Morphine prodrugs

Country Status (18)

Country Link
US (1) US5908846A (fr)
EP (1) EP0557385B1 (fr)
JP (1) JP3493434B2 (fr)
AT (1) ATE168560T1 (fr)
AU (1) AU655612B2 (fr)
CA (1) CA2095223C (fr)
DE (1) DE69129861T2 (fr)
DK (1) DK0557385T3 (fr)
ES (1) ES2121793T3 (fr)
FI (1) FI932212A0 (fr)
IE (1) IE913682A1 (fr)
IL (1) IL99905A (fr)
NO (1) NO931766D0 (fr)
NZ (1) NZ240349A (fr)
PT (1) PT99513B (fr)
SE (1) SE9003665D0 (fr)
WO (1) WO1992008459A1 (fr)
ZA (1) ZA918512B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4403709A1 (de) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
JPH07267862A (ja) * 1994-03-29 1995-10-17 Sekisui Chem Co Ltd 経皮吸収貼付剤
AU5108596A (en) * 1995-03-14 1996-10-02 Mundipharma Gmbh Morphine-3-esters
DE19508664C2 (de) * 1995-03-14 2001-08-23 Christian Mignat Verwendung von Morphin-3-estern, Morphin-3-ester als solche und Verfahren zu deren Herstellung
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19602962A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
KR20030051760A (ko) 2000-10-30 2003-06-25 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US20040097472A1 (en) * 2000-11-14 2004-05-20 West Simon Michael Complexes of phosphate derivatives
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CA2448665C (fr) * 2001-06-05 2013-01-29 Control Delivery Systems Composes analgesiques a liberation continue
EP1420797A4 (fr) * 2001-07-27 2005-03-02 Vital Health Sciences Pty Ltd Therapie dermique mettant en oeuvre des derives de phosphate d'agents de transfert electroniques
JP4624673B2 (ja) * 2001-12-13 2011-02-02 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 化合物の経皮輸送
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
WO2004039317A2 (fr) * 2002-10-25 2004-05-13 Euro-Celtique S.A. Analogues et promedicaments de buprenorphine
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
KR20060054346A (ko) * 2003-07-25 2006-05-22 유로-셀띠끄 소시에떼 아노님 수술후 통증의 수술전 치료
ATE406372T1 (de) 2004-02-06 2008-09-15 Euro Celtique Sa Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
WO2005081825A2 (fr) 2004-02-23 2005-09-09 Euro-Celtique S.A. Dispositif de distribution transdermique d'opioides empechant une utilisation abusive et contenant des microspheres d'antagonistes d'opioides
WO2005084678A1 (fr) 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Formulations alcaloides
EP2548581A3 (fr) 2005-06-17 2013-02-20 Vital Health Sciences Pty Ltd. Support comprenant un ou plusieurs dérivés de di et/ou monophosphate (agent de transfert d'électrons) ou des complexes de ceux-ci
BRPI0621081A2 (pt) * 2005-12-23 2011-11-29 Vital Health Sciences Pty Ltd método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos
JP5313868B2 (ja) 2007-03-02 2013-10-09 テイカ製薬株式会社 経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US8784872B2 (en) 2007-11-19 2014-07-22 Comgenrx, Inc. Formulation for decreasing tobacco, alcohol, drug or food consumption
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
US20100104614A1 (en) * 2008-06-27 2010-04-29 Oronsky Bryan T Providone compositions for wound healing
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
AU2010266209B2 (en) 2009-07-02 2013-09-26 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
EP2531047B1 (fr) 2010-02-05 2024-11-13 Phosphagenics Limited Vecteur comprenant du phosphate de tocophéryle non neutralisé
BR112012024835A2 (pt) 2010-03-30 2016-06-07 Phosphagenics Ltd adesivo de distribuição transdérmica
WO2011130455A1 (fr) 2010-04-13 2011-10-20 Najib Babul Compositions pharmaceutiques dermiques de 1-méthyl-2',6'-pipécoloxylidide et méthode d'utilisation
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2685992A4 (fr) 2011-03-15 2014-09-10 Phosphagenics Ltd Amino-quinoléines en tant qu'inhibiteurs de kinase
CN106999486A (zh) 2014-11-25 2017-08-01 凯姆制药公司 羟考酮的苯甲酸缀合物、苯甲酸衍生物缀合物和杂芳基羧酸缀合物
WO2017096427A1 (fr) 2015-12-09 2017-06-15 Phosphagenics Limited Formulation pharmaceutique
WO2018112512A1 (fr) 2016-12-21 2018-06-28 Phosphagenics Limited Procédé

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4891377A (en) * 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
EP0480054B1 (fr) * 1990-03-30 1996-10-02 Morimoto, Yasunori Composition absorbable par voie percutanee du chlorhydrate de morphine
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine

Also Published As

Publication number Publication date
IL99905A0 (en) 1992-08-18
NZ240349A (en) 1993-07-27
FI932212L (fi) 1993-05-14
JP3493434B2 (ja) 2004-02-03
CA2095223C (fr) 2002-12-17
ZA918512B (en) 1992-08-26
CA2095223A1 (fr) 1992-05-17
IE913682A1 (en) 1992-05-20
ES2121793T3 (es) 1998-12-16
US5908846A (en) 1999-06-01
DE69129861T2 (de) 1999-04-01
NO931766L (no) 1993-05-14
EP0557385B1 (fr) 1998-07-22
NO931766D0 (no) 1993-05-14
IL99905A (en) 1995-06-29
WO1992008459A1 (fr) 1992-05-29
PT99513A (pt) 1992-09-30
AU655612B2 (en) 1995-01-05
DE69129861D1 (de) 1998-08-27
EP0557385A1 (fr) 1993-09-01
AU8938191A (en) 1992-06-11
FI932212A0 (fi) 1993-05-14
ATE168560T1 (de) 1998-08-15
DK0557385T3 (da) 1999-04-26
PT99513B (pt) 1999-04-30
JPH06502422A (ja) 1994-03-17

Similar Documents

Publication Publication Date Title
SE9003665D0 (sv) Morphine prodrugs
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
GB2270075B (en) Substituted 2-phenyl-3-methoxypropenoate fungicides
FI954963A0 (fi) Poly-1-n-alkeeniamiineja ja näitä sisältäviä poltto- ja voiteluainekoostumuksia
MX9700886A (es) Nuevas oxazolidinonas sustituidas.
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
SI0882021T1 (en) New phenanthridines
IL104489A0 (en) Carbamates and crop protection agents containing them
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
MY106109A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
WO1992019617A3 (fr) Composes de dibenzoxazepine substituee, compositions pharmaceutiques et procedes d'utilisation
NO924672D0 (no) Metode for fremstilling av interferon alfa-2-krystaller
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
GEP20032953B (en) Antitumor Agents
NZ332215A (en) Transdermally administered dextromethorphan as antitussive agent
MX9709398A (es) N-aril-1,2,4-triazolin-5-onas.
TR199900951T2 (xx) G���s kanserinin engellenmesi i�in y�ntemler.
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
DK0662837T3 (da) Anvendelse af IL-10 til forhindring af insulinafhængig diabetes mellitus
DK0550580T3 (da) Inaktivator for uracilreduktase
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
DE59000613D1 (de) Pflaster zur transdermalen anwendung.
ATE196631T1 (de) Xamonelin-tartrat
ES2056876T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载